{
  "nctrialId": "HC-1880",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of HIV-335 (integrase inhibitor) in Patients With Major Depressive Disorder",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of HIV-335 (integrase inhibitor) in Patients With Major Depressive Disorder",
  "sponsor": "Centre for Addiction and Mental Health",
  "indication": "Major Depressive Disorder",
  "phase": "Phase 1",
  "fileName": "HC-1880.json",
  "fileSize": 322663,
  "date": "2024-08-26",
  "completionDate": "2028-10-18",
  "drugName": "HIV-335 (integrase inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of HIV-335 (integrase inhibitor) in patients with Major Depressive Disorder. The study will enroll approximately 263 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-84 years\n- Confirmed diagnosis of Major Depressive Disorder\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1880"
}